Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for PTC Therapeutics, Inc. (PTCT : NSDQ)

• Company Description    PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States. Number of Employees: 939

• Price / Volume Information    Yesterday's Closing Price: $71.78 Daily Weekly Monthly 20 Day Moving Average: 1,069,314 shares Shares Outstanding: 80.29 (millions) Market Capitalization: $5,763.10 (millions) Beta: 0.60 52 Week High: $73.98 52 Week Low: $35.95 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 8.38% 5.54% 12 Week 47.03% 40.93% Year To Date 59.02% 39.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 500 WARREN CORPORATE CENTER DRIVE - WARREN,NJ 07059 USA ph: 908-222-7000 fax: 908-222-7231 ecavaleri@ptcbio.com http://www.ptcbio.com

• General Corporate Information    Officers Matthew B. Klein - Chief Executive Officer and Director Pierre Gravier - Chief Financial Officer Michael Schmertzler - Director Allan Jacobson - Director Stephanie S. Okey - Director Peer Information PTC Therapeutics, Inc. (CORR.) PTC Therapeutics, Inc. (RSPI) PTC Therapeutics, Inc. (CGXP) PTC Therapeutics, Inc. (BGEN) PTC Therapeutics, Inc. (GTBP) PTC Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 69366J200 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/26/26 Share - Related Items Shares Outstanding: 80.29 Most Recent Split Date: (:1) Beta: 0.60 Market Capitalization: $5,763.10 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.95 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $8.39 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 33.25% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/26/26

• Fundamental Ratios P/E Current FY Estimate: 8.56 Trailing 12 Months: 7.83 PEG Ratio: 0.26 Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 3.24 EPS Growth vs. Year Ago Period: 114.39% vs. Previous Quarter: 124.10% Sales Growth vs. Year Ago Period: 7.23% vs. Previous Quarter: 17.96% ROE 09/30/25 - -194.11 06/30/25 - -106.31 03/31/25 - -78.56 ROA 09/30/25 - 33.15 06/30/25 - 30.61 03/31/25 - 32.11 Current Ratio 09/30/25 - 2.32 06/30/25 - 3.62 03/31/25 - 3.89 Quick Ratio 09/30/25 - 2.26 06/30/25 - 3.57 03/31/25 - 3.85 Operating Margin 09/30/25 - 44.90 06/30/25 - 38.32 03/31/25 - 36.76 Net Margin 09/30/25 - 42.25 06/30/25 - 35.65 03/31/25 - 33.56 Pre-Tax Margin 09/30/25 - 41.65 06/30/25 - 37.74 03/31/25 - 36.74 Book Value 09/30/25 - -1.96 06/30/25 - -2.61 03/31/25 - -2.34 Inventory Turnover 09/30/25 - 1.71 06/30/25 - 1.79 03/31/25 - 1.98 Debt-to-Equity 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Capital 09/30/25 - - 06/30/25 - - 03/31/25 - -

Powered by Zacks Investment Research ©